Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoproliferative Disorders 6Hematologic Diseases 6Immunoproliferative Disorders 5Lymphoma, Non-Hodgkin 4Lymphatic Diseases 4Multiple Myeloma 3Lymphoma 3Vascular Diseases 2Paraproteinemias 2Lymphoma, Large B-Cell, Diffuse 2Hemostatic Disorders 2Hemorrhagic Disorders 2Blood Coagulation Disorders 2Neoplasms, Plasma Cell 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Rituximab 47Cyclophosphamide 26fludarabine 13ibrutinib 12Doxorubicin 11Vincristine 10Etoposide 10Cytarabine 10Prednisone 9Bortezomib 9pembrolizumab 7fludarabine phosphate 6Lenalidomide 6Inotuzumab Ozogamicin 6obinutuzumab 5Mycophenolic Acid 5Melphalan 5Carmustine 5tositumomab I-131 4ibritumomab tiuxetan 4Tacrolimus 4Prednisolone 4Methotrexate 4Gemcitabine 4Bendamustine Hydrochloride 4Antilymphocyte Serum 4tocilizumab 3tazemetostat 3Whole-Body Irradiation 3Vorinostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, B-Cell × dacetuzumab × Clear all
NCT00103779 2014-12-18

A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma

Seagen Inc.

Phase 1 Completed
50 enrolled
Lymphoid

Hematologic Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡